The multi-organ screening test focused on hormonal changes at this stage of life provides an extended overview of women’s health. By combining 54 blood and urine parameters with personal information, body measurements, vital signs and lifestyle habits, it explores haematological, cardiometabolic, endocrine, hepatobiliary and kidney abnormalities. It extends assessment of iron, glucose metabolism, vitamins and hormonal balance to contextualise factors related to bone health, abdominal adiposity and wellbeing at this stage of life.
High-resolution comprehensive assessment of the hematopoietic system and bone marrow. By cross-analysing the blood count, red cell indices (MCV, MCH and RDW), and iron metabolism (iron, ferritin, transferrin and transferrin saturation), the system helps assess microcytic, normocytic or macrocytic anaemia and deficiency-related anaemia (iron, B12 or folate deficiency), as well as blood count patterns associated with chronic processes, haemolysis or genetic traits such as thalassaemia minor.
Assessment of the innate and adaptive immune response. The differential white blood cell count breakdown acts as a biological indicator that offers clear evidence of active bacterial or viral infections, agranulocytosis, systemic allergic responses, hypereosinophilic syndromes of parasitic origin, or immunosuppressive states.
Ultra-specific study of platelets and their volumetric indices (MPV and PDW) whose findings allow for early identification of thrombocytopenia (bleeding risk), autoimmune destruction (ITP), or reactive or essential thrombocytosis.
Comprehensive cardiometabolic risk stratification. As a starting point, the algorithm combines anthropometric indices —primarily body mass index (BMI), waist-to-hip ratio (WHR) and waist-to-height ratio (WHtR), alongside parameters such as hypertriglyceridaemic waist (HTGW), lipid accumulation product (LAP), body adiposity index (BAI), visceral adiposity index (VAI) and conicity index (CI)— with the lipid profile, blood pressure and lifestyle habits when the required data are available. This multiparametric assessment helps evaluate underlying metabolic syndrome and contextualise cardiovascular risk.
Advanced characterization of atherosclerotic risk and vascular health. The test assesses atherogenic burden through the atherogenic coefficient (AC), atherogenic index of plasma (AIP), Castelli risk indices I and II, and triglyceride-to-HDL-c index (THI), calculated from the available lipid parameters. Apolipoprotein B, non-HDL cholesterol and the LDL-c/Lp(a) ratio extend this assessment. This approach supports assessment of dyslipidaemia and silent lipid metabolism abnormalities.
Specific evaluation of lipoprotein(a) [Lp(a)] as an independent genetic biomarker of cardiovascular risk. Being genetically determined and unresponsive to standard dietary interventions, elevated Lp(a) values serve as an independent indicator raising suspicion of an increased risk of early atherosclerosis, aortic stenosis, and ischemic or thrombotic events, even in individuals with normal LDL cholesterol (LDL-c) levels.
Assessment of carbohydrate metabolism. The combination of glucose and glycated hemoglobin (HbA1c) allows anticipating the development of hypoglycemia or hyperglycemia, prediabetes, diabetes mellitus (types 1 and 2), or the risk of acute metabolic complications.
Evaluation of endocrine pancreatic function and insulin dynamics. Through the analysis of basal insulin and mathematical models (HOMA-IR, HOMA-B, HOMA-S, QUICKI), the analysis allows measuring peripheral sensitivity with ultra-specificity and revealing hyperinsulinism or insulin resistance states, a key alteration in metabolic syndrome and type 2 diabetes.
Mapping of glandular function and feedback loops. The cross-analysis of TSH and free T4 allows detecting thyroid dysfunctions such as clinical (and even subclinical) hypothyroidism or hyperthyroidism.
Assessment of the parathyroid axis and calcium metabolism. Assessment of intact parathyroid hormone (PTH), vitamin D, calcium, albumin and phosphorus helps assess calcium metabolism abnormalities and the parathyroid axis, including patterns consistent with underactive or overactive parathyroid function.
Hormonal balance and wellbeing. FSH, estradiol, prolactin, testosterone and SHBG extend the available information on hormonal balance in relation to age, symptoms, treatments and menstrual history. Vitamins B12 and B9 allow review of possible deficiencies that may contribute to the context of mood changes or concentration difficulties. The study does not aim to determine whether a woman has reached menopause or provide a comprehensive assessment of her hormonal function.
Assessment of hepatocellular function, biliary excretion, and liver disease screening. The enzyme profile (ALP, AST, ALT and GGT) helps assess cholestasis and hepatocellular abnormalities of inflammatory, metabolic or toxic origin. Interpretation alongside albumin and metabolic context contributes to assessment of possible liver disorders.
Non-invasive stratification of liver health. The system integrates indices and ratios calculable from the comprehensive profile’s parameters, together with age, body measurements, blood pressure and the required history. Depending on the availability of these data, it explores three key dimensions:
- Fat accumulation (NAFLD/MASLD): Assesses patterns associated with steatosis through the Fatty Liver Index (FLI), Hepatic Steatosis Index (HSI), K-NAFLD Score, Liver Fat Score (LFS), NAFLD Logit Score (NLS) and NAFLD Ridge Score (NRS).
- Steatohepatitis (NASH/MASH): Guides assessment of patterns associated with steatohepatitis through the acNASH model, FAT Score, GHOLAM Score and HAIR Score.
- Fibrosis and subclinical cirrhosis: Stratifies fibrosis risk and patterns consistent with advanced liver damage through the AST-to-Platelet Ratio Index (APRI), BAAT and BARD Scores, FIB-4, FibroMeter, Forns Fibrosis Index (FFI) and NAFLD Fibrosis Score (NFS).
Biliary tree screening. A coordinated increase in alkaline phosphatase and GGT raises suspicion of cholestasis or choledocholithiasis.
Striated muscle tissue integrity and lean mass assessment. Assessment of muscle wasting or loss (sarcopenia) is supported by the creatinine-to-cystatin C ratio, an indirect indicator related to muscle mass. Interpretation is combined with body measurements, age and clinical history.
Bone remodeling assessment. Assessment of calcium, phosphorus, alkaline phosphatase (ALP), vitamin D and PTH helps explore mineral metabolism and bone remodelling abnormalities, such as vitamin D deficiency and patterns consistent with impaired mineralisation. These findings provide context for bone health assessment at this stage of life.
Renal filtration and glomerular function. Creatinine, cystatin C and the urinary albumin-to-creatinine ratio (ACR) help assess glomerular filtration and abnormal albumin excretion. Combining them with clinical history and metabolic findings helps contextualise possible kidney function changes and patterns of kidney damage.
Fluid and Electrolyte Balance. Combined assessment of sodium, potassium, calcium, albumin and phosphorus may indicate electrolyte and mineral imbalances. Interpretation alongside kidney function, treatments and clinical information guides assessment of identified abnormalities.
